Primary biliary cirrhosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 20: | Line 20: | ||
* '''2''' '''Immunomodulator''' | * '''2''' '''Immunomodulator''' | ||
** 2.1 '''[[Glucocorticoid]] ''' | ** 2.1 '''[[Glucocorticoid]] ''' | ||
*** Preferred regimen : | *** Preferred regimen :[[Budesonide]] 6 to 9 mg per day PO '''(contraindicated for patients who have hypersensitivity to budesonide)''' | ||
*** Alternative regimen:[[Cyclosporine]]: 5-10 mg PO q24h | |||
*** | |||
* '''3''' '''Farnesoid-X-receptor (FXR) agonist''' | * '''3''' '''Farnesoid-X-receptor (FXR) agonist''' | ||
**3.1 Obetocholic acid | **3.1 Obetocholic acid |
Revision as of 19:44, 5 February 2018
Primary Biliary Cirrhosis Microchapters |
Differentiating Primary Biliary Cirrhosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary biliary cirrhosis medical therapy On the Web |
American Roentgen Ray Society Images of Primary biliary cirrhosis medical therapy |
Risk calculators and risk factors for Primary biliary cirrhosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]
Overview
Pharmacologic medical therapies for Primary biliary cirrhosis include Immunomodulators,antifibrotics and anticholestatics. The anticholestatic Ursodeoxycholic acid (UDCA) is recommended as the first line medical therapy for PBC.
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
- Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
- Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
- Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Primary biliary cirrhosis
- 1 Anticholestatics
- 1.1 Preferred regimen : Ursodeoxycholic acid (UDCA) 13-15 mg PO q12h for 10-21 days (Contraindications/specific instructions)
- 2 Immunomodulator
- 2.1 Glucocorticoid
- Preferred regimen :Budesonide 6 to 9 mg per day PO (contraindicated for patients who have hypersensitivity to budesonide)
- Alternative regimen:Cyclosporine: 5-10 mg PO q24h
- 2.1 Glucocorticoid
- 3 Farnesoid-X-receptor (FXR) agonist
- 3.1 Obetocholic acid
- 4 Peroxisome proliferator-activated receptor agonist